These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 8799695

  • 1. Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog.
    Giustina A, Desenzani P, Perini P, Deghenghi R, Bugari G, Wehrenberg WB, Giustina G.
    Endocr Res; 1996 May; 22(2):159-74. PubMed ID: 8799695
    [Abstract] [Full Text] [Related]

  • 2. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
    Massoud AF, Hindmarsh PC, Matthews DR, Brook CG.
    Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) response to GH-releasing peptide-6 in patients with insulin-dependent diabetes mellitus.
    Villas-Boas Weffort RF, Ramos-Dias JC, Chipoch C, Lengyel AM.
    Metabolism; 1997 Jun; 46(6):706-10. PubMed ID: 9186309
    [Abstract] [Full Text] [Related]

  • 4. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 5. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 6. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E, Di Vito L, Ramunni J, Gianotti L, Giordano R, Deghenghi R, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [Abstract] [Full Text] [Related]

  • 7. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone.
    Giustina A, Bonfanti C, Licini M, Ragni G, Stefana B.
    Regul Pept; 1997 May 14; 70(1):49-54. PubMed ID: 9250581
    [Abstract] [Full Text] [Related]

  • 8. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
    Ismail IS, Scanlon MF, Peters JR.
    Clin Endocrinol (Oxf); 1993 Feb 14; 38(2):149-57. PubMed ID: 8094648
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.
    Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1994 Aug 14; 79(2):456-60. PubMed ID: 8045963
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Metabolism; 1997 Jan 14; 46(1):83-8. PubMed ID: 9005975
    [Abstract] [Full Text] [Related]

  • 11. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Mar 14; 20(3):122-7. PubMed ID: 9186817
    [Abstract] [Full Text] [Related]

  • 12. Absence of desensitization by hexarelin to subsequent GH releasing hormone-mediated GH secretion in patients with anorexia nervosa.
    Popovic V, Micic D, Djurovic M, Obradovic S, Casanueva FF, Dieguez C.
    Clin Endocrinol (Oxf); 1997 May 14; 46(5):539-43. PubMed ID: 9231048
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess.
    Giustina A, Bussi AR, Deghenghi R, Imbimbo B, Licini M, Poiesi C, Wehrenberg WB.
    J Endocrinol; 1995 Aug 14; 146(2):227-32. PubMed ID: 7561633
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone (GH) response to GH-releasing peptide-6 in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
    Catalina PF, Mallo F, Andrade MA, García-Mayor RV, Diéguez C.
    J Clin Endocrinol Metab; 1998 Oct 14; 83(10):3663-7. PubMed ID: 9768681
    [Abstract] [Full Text] [Related]

  • 15. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E, Gianotti L, Arvat E, Ramunni J, Valetto MR, Broglio F, Rolla M, Cavagnini F, Müller EE.
    J Clin Endocrinol Metab; 1999 Jan 14; 84(1):285-90. PubMed ID: 9920097
    [Abstract] [Full Text] [Related]

  • 16. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1995 Mar 14; 80(3):942-7. PubMed ID: 7883854
    [Abstract] [Full Text] [Related]

  • 17. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S, Razzore P, Arvat E, Oleandri SE, Rossetto R, Ciccarelli E, Camanni F, Ghigo E.
    J Endocrinol Invest; 1997 Nov 14; 20(10):597-602. PubMed ID: 9438917
    [Abstract] [Full Text] [Related]

  • 18. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH.
    Arvat E, di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E.
    Peptides; 1997 Nov 14; 18(6):885-91. PubMed ID: 9285939
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.
    Micić D, Macut D, Popović V, Kendereski A, Sumarac-Dumanović M, Zorić S, Dieguez C, Casanueva FF.
    Metabolism; 1999 Apr 14; 48(4):525-30. PubMed ID: 10206449
    [Abstract] [Full Text] [Related]

  • 20. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    Neuroendocrinology; 1995 Jan 14; 61(1):51-6. PubMed ID: 7731498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.